Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.34M
Last updated: Nov 17, 2026 at 4:43 PM ET
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Statistics
Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a market cap of $4.34M and an enterprise value of $1.28M. Its share count is up 98.56% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 70.45% below the market cap, as cash exceeds debt.
| Market Cap | $4.34M |
|---|---|
| Enterprise Value | $1.28M |
| Latest price (Nov 17, 2026) | $1.88 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Aug 13, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 83.81% over 52 weeks and trades 70.91% above its 50-day average.
| Beta (1Y) | 1.76 |
|---|---|
| 52-Week Change | -83.81% |
| 1-Month Change | +77.36% |
| 3-Month Change | +14.63% |
| 6-Month Change | -62.17% |
| Total Return (1Y) | -83.81% |
| Total Return (3Y CAGR) | -35.45% |
| Return vs SPY (1Y) | -95.80% |
| Max Drawdown (1Y) | -92.90% |
| Max Drawdown (3Y) | -96.80% |
| Sharpe Ratio (1Y) | -1.65 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $1.10 |
| 200-Day Average | $3.58 |
| 52-Week Range | $0.82 to $12.50 |
| RSI (14 Days) | 76.4 |
| Average Volume (20 Days) | 110.33K |
Financial Position
Current assets cover 6.26x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.26x |
|---|---|
| Quick Ratio | 6.26x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -347.86% and return on assets is -292.37% over the last 12 months.
| Return on Equity (ROE) | -347.86% |
|---|---|
| Return on Assets (ROA) | -292.37% |
Scores
CVKD has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$555 |
| Operating Income | -$10.19M |
| Pretax Income | -$10.10M |
| Net Income | -$10.10M |
| Reported EPS (TTM) | -$4.90 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 83.82% of the $3.46M in total assets.
| Cash and Equivalents | $3.06M |
|---|---|
| Total Debt | $0 |
| Net Cash | $3.06M |
| Net Cash Per Share | $0.75 |
| Working Capital | $2.90M |
| Shareholder Equity | $2.90M |
| Book Value Per Share | $0.72 |
| Total Assets | $3.46M |
| Total Liabilities | $551.34K |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$9.72M |
|---|---|
| FCF Per Share | -$2.73 |
| Depreciation and Amortization | $2.01K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -60.63% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -60.63% |
Dividends and Yields
CVKD does not pay a dividend.
| Buyback Yield | -86.48% |
|---|---|
| Shareholder Yield | -86.48% |
Stock Splits
The last split was a 1-for-15 reverse split on Aug 20, 2024.
| Last Split Date | Aug 20, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:15 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CVKD
What is CVKD's market cap?
Cadrenal Therapeutics, Inc. Common Stock has a market cap of $4.34M. Its enterprise value, which adds debt and subtracts cash, is $1.28M.
How many shares of CVKD are outstanding?
Cadrenal Therapeutics, Inc. Common Stock has 4.06M shares outstanding. The count is up 98.56% from a year earlier.
Does CVKD pay a dividend?
No. Cadrenal Therapeutics, Inc. Common Stock does not pay a dividend.
How much debt does CVKD have?
Cadrenal Therapeutics, Inc. Common Stock has $0 of total debt and $3.06M of cash and equivalents, a net cash position of $3.06M.
CVKD pages: Overview, Charting, Earnings, Forecast, Statistics, Competitors